2022

Where do research ideas come from?

Where do research ideas come from?  Do they arrive in a thunderbolt eureka moment, or do they start as an observation or hunch, requiring some time to simmer, brew, incubate and grow?  Some may evolve from an accidental or serendipitous discovery during a routine process. Observant operators of the Phoenix MICRON® retinal imaging system may

2022

Analysis of imaging, structure and function using Phoenix MICRON™ modalities expand the understanding of ocular features of Down Syndrome in mouse models

In their paper “Quantitative Analysis of Retinal Structure and Function in Two Chromosomally Altered Mouse Models of Down Syndrome”, researchers Victorino, Scott-McKean, et al leveraged the multi-modality capabilities of the Phoenix MICRON™ retinal imaging platform, to produce an image-rich research paper looking at the ocular features of Down Syndrome in two mouse models; Ts65Dn and

2021

Phoenix MICRON Spins out of Phoenix Technology Group to Better Serve Eye and Eye-Brain Researchers Globally

Bend, OR, USA, November 29, 2021 — The newly formed company, Phoenix-Micron, Inc., announced today it has completed the spin-out of the Phoenix MICRON® imaging platform from Phoenix Technology Group. This move is designed to increase focus and innovation in products designed to serve the eye and eye-brain research community. The new company, Phoenix-Micron, Inc.

2021

Creative use of the Phoenix MICRON® system to study corneal wound healing

Hampel et al use the Phoenix MICRON®  III imaging platform  in an unusual manner in their paper “Relaxin 2 is functional at the ocular surface and promotes corneal wound healing by visualizing enucleated corneas.” The Phoenix MICRON® is designed to take crisp images and videos of the rodent retina, but this article demonstrates the other

2020

The Phoenix MICRON® IV system and OCT help evaluate promising compounds for treatment of age-related macular degeneration

Age-related macular degeneration affects tens of millions of people worldwide, leading to vision impairment and blindness. Anti-VEGF treatment helps only 25-40% of patients, leaving others with no recourse to this progressive blinding disease. In their article, “Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor,” Choudhary et al explore potential treatment using

2020

A year-long longitudinal pattern dystrophy fundus study with the Phoenix MICRON® IV imaging platform

In their 2019 paper, “Novel molecular mechanisms for Prph2‐associated pattern dystrophy,” Chakraborty et al use the Phoenix MICRON® IV retinal imaging platform to longitudinally study the effect of a very specific mutation affecting the Peripherin 2 protein. Peripherin 2 is a protein in rods and cones which, if mutated, can lead to retinitis pigmentosa, cone-rod

1 2